Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: Callio Therapeutics launches with US$187 Million series A to advance multi-payload Antibody-Drug Conjugate platform through clinical proof-of-concept Callio Therapeutics launches with $187M Series A financing led by […]
Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: ENHERTU demonstrated statistically significant and clinically meaningful improvement in overall survival in patients with HER2 positive metastatic gastric cancer at interim analysis of DESTINY-Gastric04 Phase 3 trial […]
Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: SOTIO unveils promising preclinical data on SOT109, a next-gen ADC targeting Cadherin-17 (CDH17) for colorectal cancer SOTIO Biotech presented the first preclinical data on SOT109, an antibody-drug […]
Weekly Digest – March 2025 Weekly Digest – March 2025 07 Mar 2025: PinoBio announces results of dual-payload ADC platform research PinoBio presented research at World ADC London 2025, demonstrating the superior efficacy of its dual-payload ADC platform compared to […]
Weekly Digest – February 2025 Weekly Digest – February 2025 26 Feb 2025: Pyxis Oncology granted FDA fast track designation for PYX-201 monotherapy in patients with recurrent or metastatic head and neck cancer The FDA has granted Fast Track Designation […]
Weekly Digest – February 2025 Weekly Digest – February 2025 25 Feb 2025: Hansoh Pharma’s HS-20093 receives Breakthrough Therapy Designation from NMPA for Osteosarcoma Hansoh Pharma’s B7-H3-targeted ADC, HS-20093, has been granted Breakthrough Therapy Designated Drug status by China’s NMPA […]
Weekly Digest – February 2025 Weekly Digest – February 2025 24 Feb 2025: Akeso highlights collaboration between its partner Summit Therapeutics and Pfizer to explore Ivonescimab in combination with Pfizer’s ADCs Akeso announced that its partner, Summit Therapeutics, has collaborated […]
Weekly Digest – February 2025 Weekly Digest – February 2025 25 Feb 2025: MEDSIR & Debiopharm announce the first patient dosed in the WIN-B trial exploring the combination of Debio 0123 & Gilead’s Trodelvy in advanced breast cancer Debiopharm and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 27 Feb 2025: First patient dosed in a Phase 3 clinical study of anti-HER2 biparatopic ADC JSKN003 for the treatment of HER2-positive breast cancer Alphamab Oncology and CSPC have initiated […]
Weekly Digest – February 2025 Weekly Digest – February 2025 24 Feb 2025: OS Therapies forms subsidiary OS Drug Conjugates and initiates review of strategic options for its tunable ADC & drug conjugates platforms OS Therapies has launched a subsidiary, […]
